Immune Boost Capital
Arthritis National Research Foundation
◆ Investment Thesis
An evergreen impact investment fund focused on bridging the funding gap between academic discovery and commercial development for immune-mediated diseases, reinvesting 100% of returns into future innovation.
◆ About Arthritis National Research Foundation
Immune Boost Capital (IBC) is a philanthropic evergreen venture fund, a subsidiary of the Arthritis National Research Foundation, focused on investing in early-stage autoimmune diagnostics, therapeutics, and enabling technologies.[1][2] It provides catalytic proof-of-concept capital up to $500,000 to academic spinouts and emerging biotechs to bridge the funding gap between discovery and commercial development, reinvesting 100% of returns to fuel future innovation.[4][5] IBC operates independently with guidance from experienced investors, scientists, and healthcare leaders, emphasizing strategic partnerships and co-investments.[1][3]
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Tracked Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Immune Boost Capital invest in?
Immune Boost Capital invests in Biotech, Diagnostics, Drug Discovery, Medtech and Digital Health at the pre-seed and seed stages.
Which geographies does Immune Boost Capital focus on?
Immune Boost Capital focuses on Global, and is headquartered in United States.
What is Immune Boost Capital's typical check size?
Immune Boost Capital typically writes checks of $0.1M to $0.5M.
Which startups has Immune Boost Capital backed?
Immune Boost Capital has 1 tracked investment on Fusion42, including geoSurge.